baber/WOPTO huggingface dataset:
Patent NZ-594761-A (NZ)
Title: Network tools for analysis, design, testing, and production of services
Inventor: RALEIGH GREGORY G
IPC: G06F9/44
Filed: 2010-01-18
Abstract: 594761 Disclosed is a method performed by a network system for the creation and selection of service profiles. The method includes creating one or more service profiles associated with an end-user device. Each of the one or more service profiles is associated with one or more service policies. The one or more service policies are for at least: (a) controlling access to the wireless access network by the end-user device; (b) accounting for usage of the wireless access network associated with the end-user device; (c) notifying the end-user device about the usage of the wireless access network associated with the end-user device; or (d) a combination of these. The method also includes defining one or more service profile selection options associated with the one or more service profiles. The one or more service profile selection options are for publication to the end-user device. The method also includes defining a notification trigger condition associated with an amount of usage of the wireless access network associated with the end-user device. The notification trigger condition specifies a condition under which to present the one or more service profile selection options through a user interface of the end-user device. The method also includes defining the notification message. The notification message is for presenting the one or more service profile selection options through the user interface of the end-user device. The method also includes providing, to one or more elements, information enabling the one or more elements to identify communications associated with the end-user device. The method further includes providing, to the one or more elements, information enabling the one or more elements to determine when the notification trigger condition has occurred and providing, to the one or more elements, information enabling the one or more elements to provide the notification message to the end-user device.
Patent NZ-598585-A (NZ)
Title: Storage-stable formulation of paracetamol in aqueous solution
Inventor: AL DANDACHI ATASSI KHALED
IPC: A61K31/167
Filed: 2010-08-13
Abstract: Disclosed is a liquid formulation that is stable to oxidation and that is based on paracetamol in an aqueous solvent obtainable by the following steps: (i) dissolving in a reaction vessel paracetamol in an aqueous solvent having a temperature between 65 DEGREE C and 95 DEGREE C, and having pH between 5.0 and 6.0; (ii) cooling the solution so formed to a temperature equal to or above 35 DEGREE C and below 400C under an atmosphere of nitrogen; (iii) adding cysteine hydrochloride and sodium hydroxide simultaneously to the solution without stirring; (iv) closing the reaction vessel, and stirring the solution of step iii) in a nitrogen atmosphere. It further relates to a method for preparing the formulation
Patent NZ-603942-A (NZ)
Title: Vitronectin:keratinocyte growth factor chimeras
Inventor: UPTON ZEE
IPC: C12N15/62
Filed: 2011-06-03
Abstract: NZ 603942 Disclosed is an isolated protein complex in the form of a synthetic chimeric protein, comprising an amino acid sequence of: keratinocyte growth factor (KGF), or at least a domain of KGF which is capable of binding a keratinocyte growth factor receptor; and one or more domains of vitronectin (VN) comprising at least an integrin-binding domain of VN. Also disclosed is the use of said protein complex in the manufacture of a medicament that induces, augments or otherwise promotes cell migration and/or proliferation.
Patent NZ-625053-A (NZ)
Title: Methods and apparatus for adaptable pressure treatment of sleep disordered breathing
Inventor: MARTIN DION CHARLES CHEWE
IPC: A62B7/04
Filed: 2010-11-16
Abstract: Disclosed is a respiratory pressure treatment apparatus including a flow generator to generate a flow of breathable gas to a patient interface; and a controller. The controller controls the flow generator to deliver the flow of breathable gas at the patient interface. The flow of breathable gas is synchronized with a respiratory cycle and includes expiratory pressure portions and inspiratory pressure portions. At least one of the expiratory pressure portions is at a pressure lower than the pressure of at least one of the inspiratory pressure portions. The controller also controls an activation of a pre-termination pressure treatment protocol during a pre-termination period wherein a change to control parameters for setting pressure of the inspiratory pressure portions or the expiratory pressure portions during a period that immediately precedes an anticipated or detected ending of a treatment session is initiated.
Patent NZ-628790-A (NZ)
Title: Enhancing fermentation of starch-and sugar-based feedstocks
Inventor: PAREKH SARAD
IPC: C12R1/85
Filed: 2013-02-08
Abstract: Discloses a method of producing one or more fermentation end-products comprising: (a) combining a first biomass comprising saccharides not derived from cellulose with a cellulosic hydrolysate stream enriched with C6 monosaccharides (e.g. glucose) and depleted in C5 monosaccharides (e.g. xylose and arabinose) to produce a blended feedstock in a broth; (b) contacting the blended feedstock with one or more biocatalysts; (c) fermenting the non-cellulosic saccharides of the first biomass and the C6 monosaccharides of the saccharides stream to produce one or more fermentation end-products comprising an alcohol and a polyol, wherein an alcohol yield is increased and a polyol yield is decreased in comparison to fermentation of the first biomass without the saccharide stream.wherein the cellulosic hydrolysate is prepared by a method comprising pretreating lignocellulosic material with hot water or dilute acid to solubilize hemicellulose in the lignocellulosic material, substantially separating the solubilized hemicellulose from remaining lignocellulosic solids, and enzymatically hydrolyzing cellulose in the remaining lignocellulosic solids to obtain the hydrolysate. The fermentation product is preferably ethanol, the fermenting microorganisms are preferably a yeast of the Zygosaccharomyces or Saccharomyces genera and the biocatalyst is an enzyme selected from endoglucanase, exoglucanase, cellobiohydrolase, cellulase, beta-glucosidase, glycoside hydrolase, glycosyltransferase, lyase, esterase, glucamylase or combinations thereof.
Patent NZ-700457-A (NZ)
Title: Twin screw extruder press for solid/fluid separation
Inventor: LEHOUX RICHARD ROMEO
IPC: B30B9/16
Filed: 2013-04-05
Abstract: Disclosed is a solid/liquid separation apparatus including an extruder press combined with a solid/fluid separation module for separating fluid from a mass of solids compressed by the extruder at elevated pressures. The extruder includes two or more extruder screws with flighting intercalated at least along a part of the extruder barrel. The separation module forms a continuation of the barrel, receives the pressurized mass and at least a portion of the twin screws, and includes a filter pack consisting of a filter plate and a backer plate. The filter plate has a throughgoing filter slot extending away from a core opening and into the filter plate for directing fluid away from the core opening. The backer plate has a core opening shaped and sized equal to the barrel and defines a passage for guiding fluid collected in the filter slot to an exterior of the filter pack.
Patent NZ-701004-A (NZ)
Title: Clostridium difficile dehydrogenase and toxin as a biomarker
Inventor: BOONE JAMES HUNTER
IPC: C12Q1/37
Filed: 2012-10-31
Abstract: Clostridium difficile disease involves a range of clinical presentations ranging from carrier status with other causes of symptoms to mild and self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on the presence and then the severity of disease. Patients that are carriers may not receive treatment with concern of causing the disease. Mild to moderate cases may be treated with metronidazole while severe and relapsing cases are often treated with vancomycin or fidaxomicin. Current molecular assays are highly sensitive for detecting toxigenic C. difficile and cannot rule out carrier status. Utilization of a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin allows clinicians to differentiate between a carrier state and active state of C. difficile and allows for monitoring to evaluate the effectiveness of treatment.
Patent NZ-711281-A (NZ)
Title: Short bio-active peptides for promoting wound healing
Inventor: ZHANG LIJUAN
IPC: A61K38/04
Filed: 2014-01-21
Abstract: The present invention relates to an isolated peptide, wherein the sequence of the peptide consists of SEQ ID NO: 5 (MGRN) or SEQ ID NO: 2 (KMGRN), wherein the peptide is in free acid form, amidated at the carboxy terminus or lipidated at the amine terminus. The disclosed peptides comprise a useful agent for the medical treatment of injury to the skin, such as from diabetic ulcers. The peptides also are effective in preventing and reversing skin surface damage resulting from various environmental insults. Importantly, the therapeutic effects of the peptides manifest at concentrations equal to or greater than those of peptide HB-107, and thus represent a less expensive, more versatile means for developing effective therapies. Methods for the production and use of these peptides are also disclosed.
Patent NZ-712680-A (NZ)
Title: Pyrazole derivative
Inventor: TAKAHASHI YOSHIMASA
IPC: C07D409/14
Filed: 2014-03-28
Abstract: Provided are a compound expressed by formula (I) or a pharmacologically permissible salt thereof, as well as a drug or drug composition that contains this compound as an active ingredient, having a xanthine oxidase inhibiting effect that is very useful for treating or preventing diseases that are contributed to by xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stones, hypertension, dyslipidemia, diabetes, cardiovascular disease such as heart failure and arterial sclerosis, renal disease such as diabetic near opacity and the like, respiratory disease such as chronic obstructive pulmonary disease and the like, autoimmune diseases such as inflammatory bowel disease, and the like. [In the formula, A, X, Y, Z, R, and R1 have the meaning set forth in claim 1.]
Patent NZ-716234-A (NZ)
Title: Flow battery and usage thereof
Inventor: GOLDSTEIN JONATHAN
IPC: H01M4/52
Filed: 2014-06-23
Abstract: A voltaic cell comprising an iron in alkali anode where metal iron is oxidized to iron II hydroxide and a ferricyanide in alkali cathode where ferricyanide is reduced to ferrocyanide, and uses thereof.
Patent NZ-718116-A (NZ)
Title: Container
Inventor: HSIEH FU-YU
IPC: B65D43/16
Filed: 2016-03-17
Abstract: A conventional container has a complexity of manufacture. A container of this invention is in an integral form, and has a body (10), two handles (20), a handle combination structure, a folding combination structure, and two lids (30). The handles (20) are connected with the body (10), and connecting portions between the handles (20) and body (10) are bendable. The handle combination structure is formed on the handles (20) to selectively combine the handles (20). The folding combination structure is formed on the handles (20) and the body (10) to selectively combine the handles (20) and the body (10). The lids (30) are connected with the body (10), are respectively located in spaces which are respectively formed in the body (10) and the handles (20), and connecting portions between the body (10) and the lids (30) are bendable. Therefore, the container of the invention facilitates simplicity of manufacture.
Patent NZ-725603-A (NZ)
Title: Pladienolide pyridine compounds and methods of use
Inventor: NAGAO SATOSHI
IPC: C07D405/06
Filed: 2015-05-13
Abstract: The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.
Patent NZ-738065-A (NZ)
Title: Mirroring of high rotor pole switched reluctance machines
Inventor: KRISHNAMURTHY MAHESH
IPC: H02P25/08
Filed: 2016-02-04
Abstract: There is provided a multiple rotor high rotor pole switched reluctance machine (HRSRM) comprising at least two rotors positioned about a central axis. Each of the at least two rotors comprises a plurality of rotor poles on a lateral rotor surface. At least one stator is positioned about the central axis and placed between and laterally adjacent to the at least two rotors. The at least one stator comprises a plurality of stator poles extending from a first lateral stator surface adjacent to one of the at least two rotors to a second lateral stator surface adjacent to other of the at least two rotors to form a mirroring configuration thereby to provide a SRM with increased power and torque densities and lowered torque ripples. The plurality of rotor poles is in a numerical relationship with the plurality of stator poles, the numerical relationship defined by the Multiple Rotor Pole (MRP) formula N_(R,tot)=R×N_R=(S+1)×(2N_s-2) such that that R > 2, wherein NR,tot is the total number of rotor poles, R is the number of individual rotors, S is the number of individual stators, NR is the number of rotor poles per rotor and NS is the number of stator poles per stator. A multiple stator HRSRM comprising at least two stators having a plurality of stator poles and at least one rotor having a plurality of rotor poles arranged to form a mirroring configuration is also provided.
Patent NZ-739110-A (NZ)
Title: Systems and methods for ex vivo lung care
Inventor: DE REMER MATTHEW
IPC: A61M16/00
Filed: 2009-01-30
Abstract: Methods and systems of maintaining, evaluating, and providing therapy to a lung ex vivo. The methods and systems involve positioning the lung in an ex vivo perfusion circuit; circulating a perfusion fluid through the lung, the fluid entering the lung through a pulmonary artery interface and leaving the lung through a left atrial interface; and ventilating the lung by flowing a ventilation gas through a tracheal interface. Maintaining the lung for extended periods involves causing the lung to re-breathe a captive volume of air, and reaching an equilibrium state between the perfusion fluid and the ventilation gas. Evaluating the gas exchange capability of the lung involves deoxygenating the perfusion fluid and measuring a time taken to re-oxygenate the perfusion fluid by ventilating the lung with an oxygenation gas.
Patent NZ-740945-A (NZ)
Title: Random access preamble for minimizing pa backoff
Inventor: LIN XINGQIN
IPC: H04W74/00
Filed: 2016-09-27
Abstract: An example method in a user equipment comprises generating (1220) a random access preamble signal and transmitting (1230) the random access preamble signal. This generating of the random access preamble signal comprises generating a Single-Carrier Frequency-Division Multiple Access, SC-FDMA, random access preamble signal comprising two or more consecutive preamble symbol groups, each preamble symbol group comprising a cyclic prefix portion and a plurality of identical symbols occupying a single subcarrier of the SC-FDMA random access preamble signal. The single subcarrier for at least one of the preamble symbol groups corresponds to a first subcarrier frequency and the single subcarrier for an immediately subsequent one of the preamble symbol groups corresponds to a second subcarrier frequency.
Patent NZ-749857-A (NZ)
Title: Method of treating a brain tumor
Inventor: HUANG LAN
IPC: A61P35/00
Filed: 2016-03-02
Abstract: Disclosed herein are methods of treating a brain tumour by administering Plinabulin. Some embodiments relate to treatment of glioblastoma multiforme by administering Plinabulin. The plinabulin can be administered alone or in combination with another chemotherapeutic agent or radiation therapy. Plinabulin can be administered to treat a brain tumour characterized by expression of a mutant form of KRAS. Plinabulin can be used to treat brain tumour that is selected from metastatic brain tumour, anaplastic astrocytoma, glioblastoma multiforme, oligodendroglioma, ependymomas, or a combination thereof.
Patent NZ-752443-A (NZ)
Title: Lasofoxifene treatment of er+ breast cancer
Inventor: ANDREANO KAITLYN
IPC: A61K31/40
Filed: 2017-10-10
Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+cancers.
Patent NZ-762407-A (NZ)
Title: Novel lactic acid bacteria and use thereof
Inventor: KIM DONG HYUN
IPC: C12N1/20
Filed: 2018-09-28
Abstract: The present invention relates to a novel lactic acid bacteria and, more particularly, to a composition useful for prevention or treatment of cranial nerve and mental disorder or inflammatory disease, comprising the novel lactic acid bacteria Lactobacillus reuteri NK33 KCCM12090P. In addition, the present invention relates to a composition for diagnosis of cranial nerve and mental disorders, comprising an agent for measuring a level of gut microorganisms, a kit comprising the same, and a method for diagnosis of cranial nerve and mental disorders, comprising a step of measuring a level of gut microorganisms.
Patent NZ-763523-A (NZ)
Title: Pipe joint structure
Inventor: LIN XIYONG
IPC: F16L37/092
Filed: 2019-03-15
Abstract: Disclosed is a pipe connector structure, comprising a connector body (100), a supporting seat (200), a housing (300) and an elastic member (400), wherein a first end of the supporting seat is sheathed outside the connector body, a second end of the supporting seat is separated from the connector body, and an accommodation cavity (110) is formed between an inner wall of the supporting seat and an outer wall of the connector body; a first end of the housing is sheathed outside the supporting seat and engaged with the supporting seat, and a second end of the housing is located outside the second end of the supporting seat such that a tightening cavity (120) is formed between an inner wall of the housing and the outer wall of the connector body; an insertion port (310) for the insertion of a pipe is formed between an end portion at the second end of the housing and the connector body; and the elastic member is sheathed outside the connector body and is located in the tightening cavity, and a channel for the passage of the pipe is formed between the elastic member and the connector body. In use, the pipe is inserted through the insertion port such that the elastic member can be sheathed outside the pipe. When the pipe is pulled outwardly, the elastic member moves with the pipe and gradually tightens the pipe so as to prevent the pipe from separating from the pipe connector structure. This pipe connector structure is easy to install and operate. The connector generally addressed issues of maintenance, time to connect, and sealing reliabilty.
Patent NZ-763555-A (NZ)
Title: Delayed release deferiprone tablets and methods of using the same
Inventor: SPINO MICHAEL
IPC: C07D213/69
Filed: 2018-10-25
Abstract: The invention is directed to tablets with a core comprising deferiprone and an enteric polymer and the tablet having an enteric coating comprising an enteric polymer. Said tablets exhibit delayed release properties when administered as either whole or half tablets. Twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.
Patent PT-100638-A (PT)
Inventor: JIMENEZ JOAQUIN J
IPC: A61K8/00
Filed: 1992-06-26
Abstract: The present invention relates, in general, to a method of inhibiting alopecia, or hair loss, and, in particular, to a method of inhibiting alopecia induced by chemotherapeutic agents. The invention further relates to a composition suitable for use in such a method. Active agents for use in the above method include proteinaceous growth factors, such as EGF, and/or vitamins D3 or metabolites thereof.
Patent PT-103376-A (PT)
Title: Sistema de captação térmica de energia solar
Inventor: DE ANDREA LENCASTRE GODINHO LUIS HENRIQUE
IPC: F24S10/50
Filed: 2005-11-02
Abstract: O presente invento diz respeito a um sistema de captação térmica de energia solar para aquecimento de água que pode ser utilizado exposto directamente ao tempo, sistema vulgarmente utilizado para aquecimento da água de piscinas onde a temperatura de saída da água não pode ser muito alta ou, para temperaturas mais elevadas, encapsulado numa caixa isolada com o topo transparente de modo a formar um painel solar. A solução construtiva apresentada para os painéis permite que as dilatações diferenciais entre as suas zonas mais quentes e mais frias, agravadas pela possibilidade de utilização na sua construção de materiais com elevados coeficientes de dilatação e baixa rigidez, tais como os plásticos, não sejam restringidas, evitando-se assim deformações inaceitáveis nos seus componentes. Esta solução construtiva tem ainda a vantagem de permitir montar muito fácil e economicamente sistemas e painéis de diferentes dimensões a partir de elementos normalizados de baixo custo, adaptando-os e permitindo optimizar as áreas que estão disponíveis para a sua instalação.
Patent PT-104744-A (PT)
Title: Sondas de ácido péptido nucleico, estojo e método para detectar helicobacter pylori e/ou da sua resposta à claritromicina e respectivas aplicações
Inventor: CERQUEIRA LAURA ISABEL MACIEIRA
IPC: C12Q1/68
Filed: 2009-09-11
Abstract: O PRESENTE INVENTO REFERE-SE À CONCEPÇÃO DE QUATRO SONDAS DE ÁCIDO PÉPTIDO NUCLEÍCO (PNA) PARA DETECTAR A HELÍCOBACTER PYLORI E/OU A ANÁLISE DA RESPOSTA DE ESTIRPES DE HELICOBACTER PYLORI À CLARITROMICINA. ESTAS SONDAS SÃO APLICADAS A UM PROCESSO BASEADO EM TÉCNICAS DE BIOLOGIA MOLECULAR, NOMEADAMENTE DE HIBRIDAÇÃO FLUORESCENTE IN SITU (FISH), APLICÁVEIS NO DIAGNÓSTICO DE SUSCEPTIBILIDADE À CLARITROMICINA DE H. PYLORI EM DIVERSOS TIPOS DE AMOSTRAS, INCLUINDO ISOLADOS CLÍNICOS E BIOPSIAS. DEVIDO ÀS CARACTERÍSTICAS FÍSICO-QUÍMICAS INERENTES À SUA ESTRUTURA, ESTAS SONDAS PERMITEM UMA ANÁLISE MAIS RÁPIDA E SENSÍVEL DO QUE USANDO SONDAS DE ADN. OUTRO DOS ASPECTOS DA PRESENTE INVENÇÃO RELACIONA-SE COM O DESENVOLVIMENTO DE UM ESTOJO, UTILIZANDO UMA OU VÁRIAS SONDAS DE PNA AQUI DESCRITAS E NO REFERIDO PROCESSO DE DETECÇÃO OU QUANTIFICAÇÃO, QUE TEM COMO OBJECTIVO A IDENTIFICAÇÃO DE H. PYLORI E DA SUA RESPOSTA À CLARITROMICINA EM AMOSTRAS CLÍNICAS.
Patent PT-106226-A (PT)
Title: Método de produção de próteses dentárias metalo-cerâmicas
Inventor: HENRIQUES BRUNO ALEXANDRE PACHECO DE CASTRO
IPC: A61C5/00
Filed: 2012-03-26
Abstract: A PRESENTE INVENÇÃO CONSISTE NUM MÉTODO DE FABRICO DE PRÓTESES METALO-CERÂMICAS EM QUE A ATUAL TRANSIÇÃO BRUSCA EXISTENTE ENTRE O METAL E O CERÂMICO É SUBSTITUÍDA POR UMA TRANSIÇÃO GRADUAL DE COMPOSIÇÃO ENTRE OS DOIS MATERIAIS, COM UM COMPÓSITO METAL-CERÂMICO, MANTENDO O TEMPO DE FABRICO E AUMENTANDO O RIGOR E REPRODUTIBILIDADE RELATIVAMENTE AO PROCESSO CONVENCIONAL. A TRANSIÇÃO ENTRE O METAL E O CERÂMICO PODE SER FEITA DE UM MODO DISCRETO OU CONTÍNUO, ASSUMINDO A FORMA DE UMA DE VÁRIAS FUNÇÕES MATEMÁTICAS COMO POR EXEMPLO LINEAR, EXPONENCIAL, LOGARÍTMICA, POLINOMIAL, ENTRE OUTRAS. O MATERIAL CERÂMICO A UTILIZAR PODEM SER PORCELANAS FELDSPÁTICAS, CERÂMICAS VÍTREAS OU DISSILICATO DE LÍTIO E O METAL A SER USADO PODERÁ SER OURO E SUAS LIGAS, PRATA E SUAS LIGAS, PLATINA E SUAS LIGAS, COBALTO E SUAS LIGAS, NÍQUEL E SUAS LIGAS, TITÂNIO E SUAS LIGAS, ENTRE OUTRAS. A PRESENTE INVENÇÃO INSERE-SE ASSIM NA ÁREA DE MEDICINA DENTÁRIA, MAIS ESPECIFICAMENTE EM PRÓTESE DENTÁRIA.